Evidera, a leading provider of evidence-based solutions for the healthcare industry, is pleased to announce the release of the Alzheimer’s Disease ACE simulator. Bringing to bear more than two decades of experience in modeling AD, Evidera scientists have developed the AD ACE, a comprehensive multi-application disease simulator designed to address evolving commercial and regulatory needs.
“We are very excited about the AD ACE and what it brings to the field. It is specifically designed to assess interventions from the earliest stage of disease, including the transition from normal cognitive function, through to severe disease,” said Jaime Caro, Evidera’s Chief Scientist. He will present the AD ACE model at the upcoming International PharmacoEconomic Conference on Alzheimer’s Disease (www.ipecad.org) in November.
AD ACE was designed to address the complex interactions between multiple components of AD pathology (e.g., biomarkers, cognition, behavior, function) and their role in disease progression. It also considers interrelated clinical, epidemiologic and economic outcomes, providing a platform that will allow for rapid incorporation of intervention-specific data.
Programmed in MS Excel®, the AD ACE is very transparent and was designed to meet HTA agency requirements for formal submissions. It can also be used by internal stakeholders and other decision makers. It is readily modified to meet the specific features of the therapy or diagnostic of interest. It will support commercial strategy development, inform clinical trial design, and allow for a variety of economic analyses. It is driven by the latest science in the field, and is extensively validated and well documented.
To gain access to the AD ACE, or for more information, please contact us to speak with an Evidera scientist. For recent publications, presentations, and other supporting information, please visit preview.evidera.com/ACE.